Eugene William St. Clair
W. Lester Brooks, Jr. Distinguished Professor of Medicine
The main focus of my research is the pathogenesis and treatment of rheumatoid arthritis (RA). This work has been conducted using patient-oriented research methodologies in collaboration with basic scientists and other clinical investigators. A major area of interest has been the development of novel therapies for RA, which has primarily included studies of novel biologics. Another important area of investigation has been the possible role of nitric oxide in the pathogenesis of RA.
My research is conducted in our Clinical Trials Unit which is built around a staff of three clinical research coordinators and a collaborative relationship with Dr. William E. Wilkinson, a Ph.D. biostatistician. Our group has been involved in numerous clinical trials sponsored by the pharmaceutical industry. Another important project has been a study of doxycycline therapy in RA, which has been supported by the National Institutes of Health (NIH). Recently, we have
begun an epidemiologic study of SLE in collaboration with Glinda Cooper, an epidemiologist from the National Institutes of Environmental Health Services in the Research Triangle Park. The General Clinical Research Center, an NIH-supported facility, has frequently served as the site for our research.
The current biologic therapies under investigation in patients with RA include a peptide vaccine, IL-4, IL-10, and anti-tumor necrosis factor-à chimeric monoclonal antibody (anti-TNF). The peptide vaccine consists of a "shared HLA-DRB1 epitope", a short amino acid sequence common to the -chain of those HLA-DR molecules associated with RA. IL-4 and IL-10 are inhibitory cytokines that ameliorate arthritis in experimental animal models and are in the early stages of development as a possible treatment for human disease. The most promising of the novel biologics are those agents inhibiting TNF. Our center is now involved in a phase III clinical trial of anti-TNF in patients with RA, a study involving over 20 other sites in the United States and Europe. I am also principal investigator of an NIH-sponsored study investigating the treatment efficacy of doxycycline in RA and the ability of this antibiotic to suppress collagenase activity in vivo. The work involving nitric oxide has been supported by a Specialized Center for Research in RA (Barton F. Haynes, M. D., Principal Investigator). Other current studies include a clinical trial of DHEA in SLE, and the epidemiologic study of SLE, which is based in North and South Carolina and will examine the relationship between environmental exposures and the incidence of disease.
I have been a consultant for several pharmaceutical companies who are developing new therapies for RA. In addition, I have served as a consultant on NIH study sections for applications related to clinical trials of new anti-rheumatic therapies. I have also organized a Sjogren's Syndrome Clinic at Duke that attracts referrals from the southeastern part of the United States. I have also spoken at the Annual Scientific Meeting of the American College of
Rheumatology on subjects related to my research and clinical interests, including Sjogren's Syndrome, vasculitis, and autoantibodies. Finally, I am developing an investigator's network in the southeastern United States, which should provide the patient base and infrastructure to conduct large clinical trials in rheumatology.
Key words: rheumatoid arthritis, biologics, clinical trials, Sjogren's syndrome, systemic lupus erythematosus, nitric oxide
My research is conducted in our Clinical Trials Unit which is built around a staff of three clinical research coordinators and a collaborative relationship with Dr. William E. Wilkinson, a Ph.D. biostatistician. Our group has been involved in numerous clinical trials sponsored by the pharmaceutical industry. Another important project has been a study of doxycycline therapy in RA, which has been supported by the National Institutes of Health (NIH). Recently, we have
begun an epidemiologic study of SLE in collaboration with Glinda Cooper, an epidemiologist from the National Institutes of Environmental Health Services in the Research Triangle Park. The General Clinical Research Center, an NIH-supported facility, has frequently served as the site for our research.
The current biologic therapies under investigation in patients with RA include a peptide vaccine, IL-4, IL-10, and anti-tumor necrosis factor-à chimeric monoclonal antibody (anti-TNF). The peptide vaccine consists of a "shared HLA-DRB1 epitope", a short amino acid sequence common to the -chain of those HLA-DR molecules associated with RA. IL-4 and IL-10 are inhibitory cytokines that ameliorate arthritis in experimental animal models and are in the early stages of development as a possible treatment for human disease. The most promising of the novel biologics are those agents inhibiting TNF. Our center is now involved in a phase III clinical trial of anti-TNF in patients with RA, a study involving over 20 other sites in the United States and Europe. I am also principal investigator of an NIH-sponsored study investigating the treatment efficacy of doxycycline in RA and the ability of this antibiotic to suppress collagenase activity in vivo. The work involving nitric oxide has been supported by a Specialized Center for Research in RA (Barton F. Haynes, M. D., Principal Investigator). Other current studies include a clinical trial of DHEA in SLE, and the epidemiologic study of SLE, which is based in North and South Carolina and will examine the relationship between environmental exposures and the incidence of disease.
I have been a consultant for several pharmaceutical companies who are developing new therapies for RA. In addition, I have served as a consultant on NIH study sections for applications related to clinical trials of new anti-rheumatic therapies. I have also organized a Sjogren's Syndrome Clinic at Duke that attracts referrals from the southeastern part of the United States. I have also spoken at the Annual Scientific Meeting of the American College of
Rheumatology on subjects related to my research and clinical interests, including Sjogren's Syndrome, vasculitis, and autoantibodies. Finally, I am developing an investigator's network in the southeastern United States, which should provide the patient base and infrastructure to conduct large clinical trials in rheumatology.
Key words: rheumatoid arthritis, biologics, clinical trials, Sjogren's syndrome, systemic lupus erythematosus, nitric oxide
Current Appointments & Affiliations
- W. Lester Brooks, Jr. Distinguished Professor of Medicine, Medicine, Rheumatology and Immunology, Medicine 2012
- Professor of Medicine, Medicine, Rheumatology and Immunology, Medicine 2001
- Chief, Division of Rheumatology and Immunology, Medicine, Rheumatology and Immunology, Medicine 2007
- Professor in Immunology, Immunology, Basic Science Departments 2003
Contact Information
- 34229 Hosp South, Durham, NC 27710
- Duke Box 3874, Durham, NC 27710
-
stcla003@mc.duke.edu
(919) 684-4499
- Background
-
Education, Training, & Certifications
- Chief Resident, Medicine, Duke University 1984 - 1985
- Fellow in Rheumatology, Medicine, Duke University 1983 - 1985
- Medical Resident, Medicine, Duke University 1980 - 1983
- M.D., West Virginia University 1980
-
Previous Appointments & Affiliations
- Associate Professor of Medicine with Tenure, Medicine, Rheumatology and Immunology, Medicine 1997 - 2001
- Associate Professor of Medicine, Medicine, Rheumatology and Immunology, Medicine 1996 - 1997
- Assistant Professor of Medicine, Medicine, Rheumatology and Immunology, Medicine 1987 - 1995
- Associate in the Department of Medicine, Medicine, Clinical Science Departments 1984 - 1987
- Research
-
Selected Grants
- Immunogenicity and risk of autoimmune cross-reactivity of COVID-19 mRNA vaccines in SLE - RRF Investigator Award awarded by Rheumatology Research Foundation 2022 - 2025
- A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIB4920 IN SUBJECTS WITH SJOGREN'S SYNDROME (SS) awarded by Viela Bio, Inc. 2020 - 2025
- Subaward Agreement - Benaroya to Duke - ITN Network Deputy Director of Clinical Affairs FY21-27 awarded by Benaroya Research Institute at Virginia Mason 2021 - 2023
- Subaward Agreement - BRI Immune Tolerance Network FY22ITN355 - Protocol Chair - Year 4 awarded by Benaroya Research Institute at Virginia Mason 2019 - 2023
- Subaward Agreement - Benaroya to Duke - ITN Network Deputy Director of Clinical Affairs awarded by Benaroya Research Institute at Virginia Mason 2020 - 2021
- Immunological biomarker studies in myasthenia gravis awarded by National Institutes of Health 2014 - 2020
- Subaward Agreement - Benaroya to Duke - Immune Tolerance Network awarded by Benaroya Research Institute at Virginia Mason 2011 - 2020
- BMS-IM101-603 awarded by Bristol-Myers Squibb Company 2017 - 2019
- Training Program in Inflammatory and Immunological Diseases awarded by National Institutes of Health 1980 - 2017
- Supplement from NIAID for Remaining ACE Invoices awarded by National Institute of Allergy and Infectious Diseases 2013 - 2017
- Mechanisms of B Cell Responses in Autoimmune Disease awarded by National Institutes of Health 2003 - 2017
- A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Subjects with Active Sjögren¿s Syndrome awarded by Lilly USA, LLC 2016 - 2017
- Mechanisms of Insulin Resistance in Rheumatoid Arthritis awarded by National Institutes of Health 2008 - 2015
- Scleroderma Cyclophosphamide or Transplantation (SCOT) Trial-Option 2 awarded by National Institutes of Health 2012 - 2013
- Mechanisms of Insulin Resistance in Rheumatoid Arthritis awarded by National Institutes of Health 2008 - 2013
- Scleroderma Cyclophosphamide or Transplantation (SCOT) Trial awarded by National Institutes of Health 2011 - 2012
- National Collaborative Study of Stem Cell Transplantation for Autoimmune Disease awarded by National Institutes of Health 2011
- Abatacept Vs TNF Blockade in Early Rheumatoid Arthritis: Planning for a Randomized, Double-Blind, Placebo-Controlled Trial awarded by National Institutes of Health 2007 - 2009
- Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants awarded by National Institutes of Health 2006 - 2009
- Mentored Clinical Research Scholar Program awarded by National Institutes of Health 2002 - 2006
- General Clinical Research Center awarded by National Institutes of Health 1998 - 2006
- Novel Therapeutic Targets in Rheumatoid Arthritis awarded by National Institutes of Health 1999 - 2004
- same awarded by National Institutes of Health 1987 - 2001
- The Carolina Lupus Research Study awarded by National Institutes of Health 1997 - 1999
- Specialized Center Of Research In Rheumatoid Arthritis awarded by National Institutes of Health 1987 - 1999
- General Clinical Research Center (Cru) awarded by National Institutes of Health 1975 - 1998
- Intravenous Doxycycline For Rheumatoid Arthritis awarded by National Institutes of Health 1994 - 1998
- Specialized Center Of Research In Rheumatoid Arthritis awarded by National Institutes of Health 1987 - 1997
-
External Relationships
- Abcuro, Inc.
- Bristol-Myers Squibb
- CSL Behring LLC
- Horizon Therapeutics (purchased Viela Bio)
- Immunovant
- Janssen Pharmaceuticals (Johnson & Johnson)
- Rheos Medicines, Inc.
- Rise Therapeutics
- Sonoma Biotherapeutics
- UpToDate, Inc
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Sullivan, Keith M., Navneet S. Majhail, Christopher Bredeson, Paul A. Carpenter, Soumya Chatterjee, Leslie J. Crofford, George E. Georges, et al. “Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.” Biol Blood Marrow Transplant 24, no. 10 (October 2018): 1961–64. https://doi.org/10.1016/j.bbmt.2018.06.025.Full Text Open Access Copy Link to Item
-
St Clair, E William. “In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.” Ann Intern Med 169, no. 6 (September 18, 2018): JC33. https://doi.org/10.7326/ACPJC-2018-169-6-033.Full Text Link to Item
-
St Clair, E William, Alan N. Baer, Chungwen Wei, Ghaith Noaiseh, Anne Parke, Andreea Coca, Tammy O. Utset, et al. “Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.” Arthritis Rheumatol 70, no. 9 (September 2018): 1470–80. https://doi.org/10.1002/art.40513.Full Text Link to Item
-
Rhee, Rennie L., John C. Davis, Linna Ding, Fernando C. Fervenza, Gary S. Hoffman, Cees G. M. Kallenberg, Carol A. Langford, et al. “The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.” Clin J Am Soc Nephrol 13, no. 2 (February 7, 2018): 251–57. https://doi.org/10.2215/CJN.04160417.Full Text Link to Item
-
Fudim, Marat, Matthew P. Thorpe, Leslie L. Chang, E William St Clair, Lynne M. Hurwitz Koweek, and Andrew Wang. “Cardiovascular Imaging With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Fibroinflammatory Disorders.” Jacc Cardiovasc Imaging 11, no. 2 Pt 2 (February 2018): 365–68. https://doi.org/10.1016/j.jcmg.2017.10.020.Full Text Link to Item
-
Wallace, Zachary S., Eli M. Miloslavsky, Matthew Cascino, Sebastian H. Unizony, Na Lu, Gary S. Hoffman, Cees G. M. Kallenberg, et al. “Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.” Arthritis Care Res (Hoboken) 69, no. 7 (July 2017): 1004–10. https://doi.org/10.1002/acr.23099.Full Text Link to Item
-
Merkel, Peter A., Gang Xie, Paul A. Monach, Xuemei Ji, Dominic J. Ciavatta, Jinyoung Byun, Benjamin D. Pinder, et al. “Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.” Arthritis Rheumatol 69, no. 5 (May 2017): 1054–66. https://doi.org/10.1002/art.40034.Full Text Link to Item
-
Clain, J. M., A. M. Hummel, J. H. Stone, F. C. Fervenza, G. S. Hoffman, C. G. M. Kallenberg, C. A. Langford, et al. “Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.” Clin Exp Immunol 188, no. 1 (April 2017): 174–81. https://doi.org/10.1111/cei.12925.Full Text Link to Item
-
Cartin-Ceba, Rodrigo, Divya Indrakanti, Ulrich Specks, John H. Stone, Gary S. Hoffman, Cees G. M. Kallenberg, Carol A. Langford, et al. “The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.” Arthritis Rheumatol 69, no. 1 (January 2017): 169–75. https://doi.org/10.1002/art.39822.Full Text Link to Item
-
Geetha, Duvuru, Sanjeev Sethi, An S. De Vriese, Ulrich Specks, Cees G. M. Kallenberg, Noha Lim, Robert Spiera, et al. “Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.” Am J Nephrol 46, no. 3 (2017): 231–38. https://doi.org/10.1159/000480443.Full Text Link to Item
-
Shiboski, Caroline H., Stephen C. Shiboski, Raphaèle Seror, Lindsey A. Criswell, Marc Labetoulle, Thomas M. Lietman, Astrid Rasmussen, et al. “2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.” Arthritis Rheumatol 69, no. 1 (January 2017): 35–45. https://doi.org/10.1002/art.39859.Full Text Link to Item
-
Miloslavsky, Eli M., Na Lu, Sebastian Unizony, Hyon K. Choi, Peter A. Merkel, Philip Seo, Robert Spiera, et al. “Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.” Arthritis Rheumatol 68, no. 12 (December 2016): 2945–52. https://doi.org/10.1002/art.39812.Full Text Link to Item
-
Wampler Muskardin, Theresa, Priyanka Vashisht, Jessica M. Dorschner, Mark A. Jensen, Beverly S. Chrabot, Marlena Kern, Jeffrey R. Curtis, et al. “Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.” Ann Rheum Dis 75, no. 10 (October 2016): 1757–62. https://doi.org/10.1136/annrheumdis-2015-208001.Full Text Link to Item
-
Ormseth, Michelle J., Patricia G. Yancey, Joseph F. Solus, S Louis Bridges, Jeffrey R. Curtis, MacRae F. Linton, Sergio Fazio, et al. “Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.” Arthritis Rheumatol 68, no. 9 (September 2016): 2099–2105. https://doi.org/10.1002/art.39675.Full Text Link to Item
-
Mills, John R., Divi Cornec, Surendra Dasari, Paula M. Ladwig, Amber M. Hummel, Melissa Cheu, David L. Murray, et al. “Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis.” Anal Chem 88, no. 12 (June 21, 2016): 6317–25. https://doi.org/10.1021/acs.analchem.6b00544.Full Text Link to Item
-
Unizony, Sebastian, Miguel Villarreal, Eli M. Miloslavsky, Na Lu, Peter A. Merkel, Robert Spiera, Philip Seo, et al. “Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.” Ann Rheum Dis 75, no. 6 (June 2016): 1166–69. https://doi.org/10.1136/annrheumdis-2015-208073.Full Text Link to Item
-
St Clair, E William. “ACR Presidential Address: RethinkingRheumatology: A Brave New World.” Arthritis Rheumatol 68, no. 2 (February 2016): 277–81. https://doi.org/10.1002/art.39533.Full Text Link to Item
-
Taylor, William J., and E William St Clair. “Editorial: Shifting the Goal Posts: Treatment Recommendations for Ankylosing Spondylitis and the Newly Defined Condition of Nonradiographic Axial Spondyloarthritis.” Arthritis & Rheumatology (Hoboken, N.J.) 68, no. 2 (February 2016): 265–69. https://doi.org/10.1002/art.39300.Full Text
-
Singh, Jasvinder A., Kenneth G. Saag, S Louis Bridges, Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta Vaysbrot, et al. “2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis Rheumatol 68, no. 1 (January 2016): 1–26. https://doi.org/10.1002/art.39480.Full Text Link to Item
-
Singh, Jasvinder A., Kenneth G. Saag, S Louis Bridges, Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta Vaysbrot, et al. “2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis Care Res (Hoboken) 68, no. 1 (January 2016): 1–25. https://doi.org/10.1002/acr.22783.Full Text Link to Item
-
St Clair, E William. “Introducing the New Editor of Arthritis & Rheumatology, Richard J. Bucala, MD, PhD.” Arthritis Rheumatol 67, no. 7 (July 2015): 1687–88. https://doi.org/10.1002/art.39171.Full Text Link to Item
-
Grayson, Peter C., Carmelo Carmona-Rivera, Lijing Xu, Noha Lim, Zhong Gao, Adam L. Asare, Ulrich Specks, et al. “Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.” Arthritis Rheumatol 67, no. 7 (July 2015): 1922–32. https://doi.org/10.1002/art.39153.Full Text Link to Item
-
Ranganath, Veena K., Kambiz Motamedi, Espen A. Haavardsholm, Paul Maranian, David Elashoff, Fiona McQueen, Erin L. Duffy, et al. “Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.” Arthritis Care Res (Hoboken) 67, no. 7 (July 2015): 929–39. https://doi.org/10.1002/acr.22541.Full Text Link to Item
-
Miloslavsky, E. M., U. Specks, P. A. Merkel, P. Seo, R. Spiera, C. A. Langford, G. S. Hoffman, et al. “Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.” Arthritis Rheumatol 67, no. 6 (June 2015): 1629–36. https://doi.org/10.1002/art.39104.Full Text Link to Item
-
Hinkofer, Lisa C., Amber M. Hummel, John H. Stone, Gary S. Hoffman, Peter A. Merkel, E Robert F. Spiera, William St Clair, et al. “Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis.” J Autoimmun 59 (May 2015): 43–52. https://doi.org/10.1016/j.jaut.2015.02.002.Full Text Link to Item
-
Geetha, Duvuru, Ulrich Specks, John H. Stone, Peter A. Merkel, Philip Seo, Robert Spiera, Carol A. Langford, et al. “Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.” J Am Soc Nephrol 26, no. 4 (April 2015): 976–85. https://doi.org/10.1681/ASN.2014010046.Full Text Link to Item
-
Unizony, Sebastian, Noha Lim, Deborah J. Phippard, Vincent J. Carey, Eli M. Miloslavsky, Nadia K. Tchao, David Iklé, et al. “Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.” Arthritis Rheumatol 67, no. 2 (February 2015): 535–44. https://doi.org/10.1002/art.38916.Full Text Link to Item
-
Huffman, K. M., C. F. Pieper, K. S. Hall, E. W. St Clair, and W. E. Kraus. “Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis.” Scand J Rheumatol 44, no. 2 (2015): 106–10. https://doi.org/10.3109/03009742.2014.931456.Full Text Link to Item
-
Smilek, Dawn E., and E William St Clair. “Solving the puzzle of autoimmunity: critical questions.” F1000prime Rep 7 (2015): 17. https://doi.org/10.12703/P7-17.Full Text Link to Item
-
Miloslavsky, E. M., U. Specks, P. A. Merkel, P. Seo, R. Spiera, C. A. Langford, G. S. Hoffman, et al. “Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.” Arthritis Rheumatol 66, no. 11 (November 2014): 3151–59. https://doi.org/10.1002/art.38788.Full Text Link to Item
-
AbouAssi, Hiba, K Noelle Tune, Brian Gilmore, Lori A. Bateman, Gary McDaniel, Michael Muehlbauer, Janet L. Huebner, et al. “Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis.” J Rheumatol 41, no. 10 (October 2014): 1974–79. https://doi.org/10.3899/jrheum.140224.Full Text Link to Item
-
Hershberg, Uri, Wenzhao Meng, Bochao Zhang, Nancy Haff, E William St Clair, Philip L. Cohen, Patrice D. McNair, Ling Li, Marc C. Levesque, and Eline T. Luning Prak. “Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.” Arthritis Res Ther 16, no. 1 (February 11, 2014): R51. https://doi.org/10.1186/ar4481.Full Text Link to Item
-
Batich, Kristen A., E. William St Clair, Roger E. McLendon, and John H. Sampson. “Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease.” J Clin Neurosci 20, no. 10 (October 2013): 1445–48. https://doi.org/10.1016/j.jocn.2013.01.009.Full Text Link to Item
-
Miloslavsky, E. M., U. Specks, P. A. Merkel, P. Seo, R. Spiera, C. A. Langford, G. S. Hoffman, et al. “Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.” Arthritis Rheum 65, no. 9 (September 2013): 2441–49. https://doi.org/10.1002/art.38044.Full Text Link to Item
-
Xie, Gang, Delnaz Roshandel, Richard Sherva, Paul A. Monach, Emily Yue Lu, Tabitha Kung, Keisha Carrington, et al. “Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.” Arthritis Rheum 65, no. 9 (September 2013): 2457–68. https://doi.org/10.1002/art.38036.Full Text Link to Item
-
Monach, Paul A., Roscoe L. Warner, Gunnar Tomasson, Ulrich Specks, John H. Stone, Linna Ding, Fernando C. Fervenza, et al. “Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.” Ann Rheum Dis 72, no. 8 (August 2013): 1342–50. https://doi.org/10.1136/annrheumdis-2012-201981.Full Text Link to Item
-
Specks, Ulrich, Peter A. Merkel, Philip Seo, Robert Spiera, Carol A. Langford, Gary S. Hoffman, Cees G. M. Kallenberg, et al. “Efficacy of remission-induction regimens for ANCA-associated vasculitis.” N Engl J Med 369, no. 5 (August 1, 2013): 417–27. https://doi.org/10.1056/NEJMoa1213277.Full Text Link to Item
-
Hung, Emily W., Maureen D. Mayes, Roozbeh Sharif, Shervin Assassi, Victor I. Machicao, Chitra Hosing, E William St Clair, et al. “Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.” J Rheumatol 40, no. 4 (April 2013): 455–60. https://doi.org/10.3899/jrheum.121087.Full Text Link to Item
-
St Clair, E William, Marc C. Levesque, Eline T Luning Prak, Frederick B. Vivino, Chacko J. Alappatt, Meagan E. Spychala, Josiah Wedgwood, et al. “Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.” Arthritis Rheum 65, no. 4 (April 2013): 1097–1106. https://doi.org/10.1002/art.37850.Full Text Link to Item
-
Kaul, Mala S., Sunil V. Rao, Linda K. Shaw, Emily Honeycutt, Stacy P. Ardoin, and E William St Clair. “Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study.” Arthritis Care Res (Hoboken) 65, no. 2 (February 2013): 266–73. https://doi.org/10.1002/acr.21782.Full Text Link to Item
-
Chung, Sharon A., Gang Xie, Delnaz Roshandel, Richard Sherva, Jeffrey C. Edberg, Megan Kravitz, Paul F. Dellaripa, et al. “Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.” Arthritis Rheum 64, no. 10 (October 2012): 3463–71. https://doi.org/10.1002/art.34496.Full Text Link to Item
-
Moreland, Larry W., James R. O’Dell, Harold E. Paulus, Jeffrey R. Curtis, Joan M. Bathon, E William St Clair, S Louis Bridges, et al. “A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.” Arthritis Rheum 64, no. 9 (September 2012): 2824–35. https://doi.org/10.1002/art.34498.Full Text Link to Item
-
McCallum, R. M., and E. W. St. Clair. “Cogan's Syndrome,” May 3, 2012, 299–311. https://doi.org/10.1002/9781118355244.ch27.Full Text
-
St Clair, E William. “Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.” Arthritis Rheum 64, no. 3 (March 2012): 604–8. https://doi.org/10.1002/art.34326.Full Text Link to Item
-
Tomasson, Gunnar, Maarten Boers, Michael Walsh, Michael LaValley, David Cuthbertson, Simon Carette, John C. Davis, et al. “Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).” Arthritis Care Res (Hoboken) 64, no. 2 (February 2012): 273–79. https://doi.org/10.1002/acr.20649.Full Text Link to Item
-
Monach, Paul A., Philipp Kümpers, Alexander Lukasz, Gunnar Tomasson, Ulrich Specks, John H. Stone, David Cuthbertson, et al. “Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.” Plos One 7, no. 1 (2012): e30197. https://doi.org/10.1371/journal.pone.0030197.Full Text Link to Item
-
Kelley, James M., Paul A. Monach, Chuanyi Ji, Yebin Zhou, Jianming Wu, Sumiaki Tanaka, Alfred D. Mahr, et al. “IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.” Proc Natl Acad Sci U S A 108, no. 51 (December 20, 2011): 20736–41. https://doi.org/10.1073/pnas.1109227109.Full Text Link to Item
-
Clowse, Megan E. B., Susannah C. Copland, Tsung-Cheng Hsieh, Shein-Chung Chow, Gary S. Hoffman, Peter A. Merkel, Robert F. Spiera, et al. “Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).” Arthritis Care Res (Hoboken) 63, no. 12 (December 2011): 1777–81. https://doi.org/10.1002/acr.20605.Full Text Link to Item
-
Monach, Paul A., Gunnar Tomasson, Ulrich Specks, John H. Stone, David Cuthbertson, Jeffrey Krischer, Linna Ding, et al. “Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.” Arthritis Rheum 63, no. 12 (December 2011): 3988–97. https://doi.org/10.1002/art.30615.Full Text Link to Item
-
Silva, Francisco, Philip Seo, Darrell R. Schroeder, John H. Stone, Peter A. Merkel, Gary S. Hoffman, Robert Spiera, et al. “Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.” Arthritis Rheum 63, no. 8 (August 2011): 2495–2503. https://doi.org/10.1002/art.30394.Full Text Link to Item
-
Tomasson, Gunnar, Michael Lavalley, Kahraman Tanriverdi, Javier D. Finkielman, John C. Davis, Gary S. Hoffman, W Joseph McCune, et al. “Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.” J Rheumatol 38, no. 6 (June 2011): 1048–54. https://doi.org/10.3899/jrheum.100735.Full Text Link to Item
-
Nepom, Gerald T., E William St Clair, and Laurence A. Turka. “Challenges in the pursuit of immune tolerance.” Immunol Rev 241, no. 1 (May 2011): 49–62. https://doi.org/10.1111/j.1600-065X.2011.01003.x.Full Text Link to Item
-
Suppiah, Ravi, Andrew Judge, Rajbir Batra, Oliver Flossmann, Lorraine Harper, Peter Höglund, M Kassim Javaid, et al. “A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.” Arthritis Care Res (Hoboken) 63, no. 4 (April 2011): 588–96. https://doi.org/10.1002/acr.20433.Full Text Link to Item
-
Iwata, Yohei, Takashi Matsushita, Mayuka Horikawa, David J. Dilillo, Koichi Yanaba, Guglielmo M. Venturi, Paul M. Szabolcs, et al. “Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.” Blood 117, no. 2 (January 13, 2011): 530–41. https://doi.org/10.1182/blood-2010-07-294249.Full Text Link to Item
-
Specks, U., P. A. Merkel, G. S. Hoffman, C. A. Langford, R. Spiera, P. Seo, C. G. M. Kallenberg, et al. “Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial.” Open Arthritis Journal 4, no. 1 (January 1, 2011): 1–18. https://doi.org/10.2174/1876539401104010001.Full Text
-
Desjardins, Claude, E William St Clair, and Ronald G. Ehrenberg. “Analysis of the workforce and workplace for rheumatology and the research activities of rheumatologists early in their careers.” Arthritis Rheum 62, no. 12 (December 2010): 3528–36. https://doi.org/10.1002/art.27721.Full Text Link to Item
-
Mahr, Alfred D., Jeffrey C. Edberg, John H. Stone, Gary S. Hoffman, E William St Clair, Ulrich Specks, Paul F. Dellaripa, et al. “Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.” Arthritis Rheum 62, no. 12 (December 2010): 3760–67. https://doi.org/10.1002/art.27742.Full Text Link to Item
-
Bluestone, Jeffrey A., Hugh Auchincloss, Gerald T. Nepom, Daniel Rotrosen, E William St Clair, and Laurence A. Turka. “The Immune Tolerance Network at 10 years: tolerance research at the bedside.” Nature Reviews. Immunology 10, no. 11 (November 2010): 797–803. https://doi.org/10.1038/nri2869.Full Text
-
Stone, John H., Peter A. Merkel, Robert Spiera, Philip Seo, Carol A. Langford, Gary S. Hoffman, Cees G. M. Kallenberg, et al. “Rituximab versus cyclophosphamide for ANCA-associated vasculitis.” N Engl J Med 363, no. 3 (July 15, 2010): 221–32. https://doi.org/10.1056/NEJMoa0909905.Full Text Link to Item
-
St Clair, E William. “Good and bad memories following rituximab therapy.” Arthritis Rheum 62, no. 1 (January 2010): 1–5. https://doi.org/10.1002/art.25039.Full Text Link to Item
-
Meyer, C. G., and E. W. St. Clair. “Promising Biologic Agents and Small Chemical Compounds,” December 1, 2009, 372–78. https://doi.org/10.1016/B978-032305475-1.50051-3.Full Text
-
O’Dell, J. R., J. S. Smolen, D. Aletaha, D. R. Robinson, and E. W. St. Clair. “Rheumatoid arthritis,” December 1, 2009, 1–13. https://doi.org/10.1007/978-1-84800-934-9_1.Full Text
-
St Clair, E William. “Novel targeted therapies for autoimmunity.” Curr Opin Immunol 21, no. 6 (December 2009): 648–57. https://doi.org/10.1016/j.coi.2009.09.008.Full Text Link to Item
-
Finkielman, J. D., P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E. W. St. Clair, J. C. Davis, et al. “Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.” Clinical and Experimental Rheumatology 27, no. 1 SUPPL. 52 (November 30, 2009).
-
Smolen, J. S., D. M. van der Heijde, D. Aletaha, S. Xu, J. Han, D. Baker, and E. W. St Clair. “Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.” Ann Rheum Dis 68, no. 10 (October 2009): 1535–40. https://doi.org/10.1136/ard.2008.094128.Full Text Link to Item
-
Vastesaeger, Nathan, Stephen Xu, Daniel Aletaha, E William St Clair, and Josef S. Smolen. “A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.” Rheumatology (Oxford) 48, no. 9 (September 2009): 1114–21. https://doi.org/10.1093/rheumatology/kep155.Full Text Link to Item
-
Shah, Ankoor, Louis F. Diehl, and E William St Clair. “T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia.” Clin Immunol 132, no. 2 (August 2009): 145–52. https://doi.org/10.1016/j.clim.2009.03.515.Full Text Link to Item
-
Smolen, J. S., C. Han, D. M. F. M. van der Heijde, P. Emery, J. M. Bathon, E. Keystone, R. N. Maini, et al. “Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.” Ann Rheum Dis 68, no. 6 (June 2009): 823–27. https://doi.org/10.1136/ard.2008.090019.Full Text Link to Item
-
Finkielman, J. D., P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E. W. St Clair, J. C. Davis, et al. “Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.” Clinical and Experimental Rheumatology 27, no. 1 Suppl 52 (January 2009): S45–52.
-
Oliver, A. M., and E. W. St. Clair. “Rheumatoid arthritis C. treatment and assessments,” December 1, 2008, 133–41. https://doi.org/10.1007/978-0-387-68566-3_6.Full Text
-
Mahr, Alfred D., Tuhina Neogi, Michael P. Lavalley, John C. Davis, Gary S. Hoffman, W Joseph McCune, Ulrich Specks, et al. “Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.” Arthritis Rheum 59, no. 6 (June 15, 2008): 884–91. https://doi.org/10.1002/art.23707.Full Text Link to Item
-
St Clair, E. W. “The calm after the cytokine storm: Lessons from the TGN1412 trial (Journal of Clinical Investigation (2008) 118, (1344-1347) DOI: 10.1172/JCI35382).” Journal of Clinical Investigation 118, no. 6 (June 2, 2008): 2365. https://doi.org/10.1172/JCI35382C1.Full Text
-
Yanaba, Koichi, Jean-David Bouaziz, Takashi Matsushita, Cynthia M. Magro, E William St Clair, and Thomas F. Tedder. “B-lymphocyte contributions to human autoimmune disease.” Immunol Rev 223 (June 2008): 284–99. https://doi.org/10.1111/j.1600-065X.2008.00646.x.Full Text Link to Item
-
Wung, Peter K., Troy Anderson, Kevin R. Fontaine, Gary S. Hoffman, Ulrich Specks, Peter A. Merkel, Robert Spiera, et al. “Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.” Arthritis Rheum 59, no. 5 (May 15, 2008): 746–53. https://doi.org/10.1002/art.23561.Full Text Link to Item
-
Han, Chenglong, Josef Smolen, Arthur Kavanaugh, E William St Clair, Daniel Baker, and Mohan Bala. “Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis.” Arthritis Rheum 59, no. 4 (April 15, 2008): 510–14. https://doi.org/10.1002/art.23541.Full Text Link to Item
-
St Clair, E William. “The calm after the cytokine storm: lessons from the TGN1412 trial.” J Clin Invest 118, no. 4 (April 2008): 1344–47. https://doi.org/10.1172/JCI35382.Full Text Link to Item
-
Furst, D. E., R. J. Halbert, C. O. Bingham, S. Fukudome, L. Anderson, P. Bonafede, V. Bray, et al. “Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel.” Rheumatology (Oxford, England) 47, no. 2 (February 2008): 194–99. https://doi.org/10.1093/rheumatology/kem326.Full Text
-
Levesque, Marc C., and E William St Clair. “B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.” J Allergy Clin Immunol 121, no. 1 (January 2008): 13–21. https://doi.org/10.1016/j.jaci.2007.11.030.Full Text Link to Item
-
Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue, J. L. “Measurement of fatigue in systemic lupus erythematosus: a systematic review.” Arthritis Rheum 57, no. 8 (December 15, 2007): 1348–57. https://doi.org/10.1002/art.23113.Full Text Link to Item
-
Sebastian, Jodi K., Barbara Voetsch, John H. Stone, Zurina Romay-Penabad, Grace H. Lo, Nancy B. Allen, John C. Davis, et al. “The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.” J Rheumatol 34, no. 12 (December 2007): 2446–50.Link to Item
-
Finkielman, Javier D., Peter A. Merkel, Darrell Schroeder, Gary S. Hoffman, Robert Spiera, E William St Clair, John C. Davis, et al. “Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.” Ann Intern Med 147, no. 9 (November 6, 2007): 611–19. https://doi.org/10.7326/0003-4819-147-9-200711060-00005.Full Text Link to Item
-
Han, Chenglong, Mahboob U. Rahman, Mittie K. Doyle, Joan M. Bathon, Josef Smolen, Arthur Kavanaugh, René Westhovens, E William St Clair, Daniel Baker, and Mohan Bala. “Association of anemia and physical disability among patients with rheumatoid arthritis.” J Rheumatol 34, no. 11 (November 2007): 2177–82.Link to Item
-
Cooper, Glinda S., Edward L. Treadwell, E William St Clair, Gary S. Gilkeson, and Mary Anne Dooley. “Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus.” Arthritis Rheum 57, no. 6 (August 15, 2007): 993–99. https://doi.org/10.1002/art.22894.Full Text Link to Item
-
Yanaba, Koichi, Yasuhito Hamaguchi, Guglielmo M. Venturi, Douglas A. Steeber, E William St Clair, and Thomas F. Tedder. “B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity.” J Immunol 179, no. 2 (July 15, 2007): 1369–80. https://doi.org/10.4049/jimmunol.179.2.1369.Full Text Link to Item
-
Finkielman, Javier D., Augustine S. Lee, Amber M. Hummel, Margaret A. Viss, Gregory L. Jacob, Henry A. Homburger, Tobias Peikert, et al. “ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.” Am J Med 120, no. 7 (July 2007): 643.e9-643.14. https://doi.org/10.1016/j.amjmed.2006.08.016.Full Text Link to Item
-
Visvanathan, Sudha, Joseph C. Marini, Josef S. Smolen, E William St Clair, Charles Pritchard, William Shergy, Charles Pendley, et al. “Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.” J Rheumatol 34, no. 7 (July 2007): 1465–74.Link to Item
-
Looney, R John, Betty Diamond, V Michael Holers, Marc C. Levesque, Larry Moreland, Moon H. Nahm, E William St Clair, and E William Autoimmunity Centers of Excellence Immunocompetency Committee. “Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.” Clin Immunol 123, no. 3 (June 2007): 235–43. https://doi.org/10.1016/j.clim.2007.01.001.Full Text Link to Item
-
Sebastian, Jodi K., Alfred D. Mahr, Sohail S. Ahmed, John H. Stone, Zurina Romay-Penabad, John C. Davis, Gary S. Hoffman, et al. “Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations.” J Rheumatol 34, no. 5 (May 2007): 1027–31.Link to Item
-
St Clair, E William, Larry A. Turka, Andrew Saxon, Jeffrey B. Matthews, Mohamed H. Sayegh, George S. Eisenbarth, and Jeffrey Bluestone. “New reagents on the horizon for immune tolerance.” Annu Rev Med 58 (2007): 329–46. https://doi.org/10.1146/annurev.med.58.061705.145449.Full Text Link to Item
-
Visvanathan, Sudha, Carrie Wagner, Josef Smolen, E William St Clair, Ron Hegedus, Daniel Baker, and Gregory Keenan. “IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.” Arthritis Rheum 54, no. 9 (September 2006): 2840–44. https://doi.org/10.1002/art.22054.Full Text Link to Item
-
Tedder, T. F., and E. W. St.Clair. “Reply [7].” Arthritis and Rheumatism 54, no. 7 (July 1, 2006): 2344–45. https://doi.org/10.1002/art.21938.Full Text
-
Stone, John H., Janet T. Holbrook, Matthew A. Marriott, Andrea K. Tibbs, Lourdes P. Sejismundo, Y. -. I. Min, Ulrich Specks, et al. “Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.” Arthritis Rheum 54, no. 5 (May 2006): 1608–18. https://doi.org/10.1002/art.21869.Full Text Link to Item
-
Bluestone, Jeffrey A., E William St Clair, and Laurence A. Turka. “CTLA4Ig: bridging the basic immunology with clinical application.” Immunity 24, no. 3 (March 2006): 233–38. https://doi.org/10.1016/j.immuni.2006.03.001.Full Text Link to Item
-
Smolen, Josef S., Chenglong Han, Désirée van der Heijde, Paul Emery, Joan M. Bathon, Edward Keystone, Joachim R. Kalden, et al. “Infliximab treatment maintains employability in patients with early rheumatoid arthritis.” Arthritis Rheum 54, no. 3 (March 2006): 716–22. https://doi.org/10.1002/art.21661.Full Text Link to Item
-
Smolen, Josef S., Désirée M. F. M. Van Der Heijde, E William St Clair, Paul Emery, Joan M. Bathon, Edward Keystone, Ravinder N. Maini, et al. “Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.” Arthritis Rheum 54, no. 3 (March 2006): 702–10. https://doi.org/10.1002/art.21678.Full Text Link to Item
-
Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria, W. S. “The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials.” Arthritis Rheum 54, no. 2 (February 2006): 421–32. https://doi.org/10.1002/art.21625.Full Text Link to Item
-
Savage, Christine, and E William St Clair. “New therapeutics in rheumatoid arthritis.” Rheum Dis Clin North Am 32, no. 1 (February 2006): 57–viii. https://doi.org/10.1016/j.rdc.2005.10.004.Full Text Link to Item
-
Savage, C., and E. W. St. Clair. “Erratum to "New Therapeutics in Rheumatoid Arthritis" [Rheum Dis Clin N Am 32 (1) (2006) 57-74] (DOI:10.1016/j.rdc.2005.10.004).” Rheumatic Disease Clinics of North America 32, no. 2 (January 1, 2006): 9. https://doi.org/10.1016/j.rdc.2006.05.009.Full Text
-
St Clair, E William, and Thomas F. Tedder. “New prospects for autoimmune disease therapy: B cells on deathwatch.” Arthritis Rheum 54, no. 1 (January 2006): 1–9. https://doi.org/10.1002/art.21525.Full Text Link to Item
-
Weinberg, J Brice, Thomas Lang, William E. Wilkinson, David S. Pisetsky, and E William St Clair. “Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures.” Arthritis Res Ther 8, no. 5 (2006): R140. https://doi.org/10.1186/ar2030.Full Text Link to Item
-
Wung, Peter K., Janet T. Holbrook, Gary S. Hoffman, Andrea K. Tibbs, Ulrich Specks, Y. -. I. Min, Peter A. Merkel, et al. “Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.” Am J Med 118, no. 12 (December 2005): 1416. https://doi.org/10.1016/j.amjmed.2005.06.012.Full Text Link to Item
-
Savage, C., E. W. St. Clair, and J. S. Sundy. “Emerging treatments for rheumatoid arthritis: Update.” Consultant 45, no. 9 (August 1, 2005): 984–95.
-
Seo, Philip, Yuan-I Min, Janet T. Holbrook, Gary S. Hoffman, Peter A. Merkel, Robert Spiera, John C. Davis, et al. “Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).” Arthritis Rheum 52, no. 7 (July 2005): 2168–78. https://doi.org/10.1002/art.21117.Full Text Link to Item
-
Haynes, Barton F., Judith Fleming, E William St Clair, Herman Katinger, Gabriela Stiegler, Renate Kunert, James Robinson, et al. “Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.” Science 308, no. 5730 (June 24, 2005): 1906–8. https://doi.org/10.1126/science.1111781.Full Text Link to Item
-
Merkel, Peter A., Grace H. Lo, Janet T. Holbrook, Andrea K. Tibbs, Nancy B. Allen, John C. Davis, Gary S. Hoffman, et al. “Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.” Ann Intern Med 142, no. 8 (April 19, 2005): 620–26. https://doi.org/10.7326/0003-4819-142-8-200505030-00011.Full Text Link to Item
-
Parks, Christine G., Glinda S. Cooper, Lori L. Hudson, Mary Anne Dooley, Edward L. Treadwell, E. W. St Clair, Gary S. Gilkeson, and Janardan P. Pandey. “Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype.” Arthritis Rheum 52, no. 4 (April 2005): 1148–59. https://doi.org/10.1002/art.20997.Full Text Link to Item
-
Geletka, Robin C., and E William St Clair. “Infliximab for the treatment of early rheumatoid arthritis.” Expert Opin Biol Ther 5, no. 3 (March 2005): 405–17. https://doi.org/10.1517/14712598.5.3.405.Full Text Link to Item
-
Stone, John H., Vinodh N. Rajapakse, Gary S. Hoffman, Ulrich Specks, Peter A. Merkel, Robert F. Spiera, John C. Davis, et al. “A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.” Arthritis Rheum 52, no. 3 (March 2005): 902–10. https://doi.org/10.1002/art.20938.Full Text Link to Item
-
Parks, C. G., J. P. Pandey, M. A. Dooley, E. L. Treadwell, E. W. St. Clair, G. S. Gilkeson, C. A. Feghali-Bostwick, and G. S. Cooper. “Erratum: Genetic polymorphisms in tumor necrosis factor (TNF)-α and TNF-β in a population-based study of systemic lupus erythematosus: Associations and interaction with interleukin-1α-889 C/T polymorphism (Human Immunology (2004) 65 (622)).” Human Immunology 66, no. 3 (January 1, 2005): 331. https://doi.org/10.1016/j.humimm.2005.01.013.Full Text
-
Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus, Brigid L. M. “Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting.” Arthritis Rheum 50, no. 11 (November 2004): 3427–31. https://doi.org/10.1002/art.20599.Full Text Link to Item
-
American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria, K. P. “The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.” Arthritis Rheum 50, no. 11 (November 2004): 3418–26. https://doi.org/10.1002/art.20628.Full Text Link to Item
-
St Clair, E William, Désirée M. F. M. van der Heijde, Josef S. Smolen, Ravinder N. Maini, Joan M. Bathon, Paul Emery, Edward Keystone, et al. “Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.” Arthritis Rheum 50, no. 11 (November 2004): 3432–43. https://doi.org/10.1002/art.20568.Full Text Link to Item
-
Cooper, Glinda S., Christine G. Parks, Edward L. Treadwell, E William St Clair, Gary S. Gilkeson, and Mary Anne Dooley. “Occupational risk factors for the development of systemic lupus erythematosus.” J Rheumatol 31, no. 10 (October 2004): 1928–33.Link to Item
-
Petri, Michelle A., Philip J. Mease, Joan T. Merrill, Robert G. Lahita, Mark J. Iannini, David E. Yocum, Ellen M. Ginzler, et al. “Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.” Arthritis Rheum 50, no. 9 (September 2004): 2858–68. https://doi.org/10.1002/art.20427.Full Text Link to Item
-
Parks, Christine G., Janardan P. Pandey, Mary Anne Dooley, Edward L. Treadwell, E. W. St Clair, Gary S. Gilkeson, Carol A. Feghali-Bostwick, and Glinda S. Cooper. “Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism.” Hum Immunol 65, no. 6 (June 2004): 622–31. https://doi.org/10.1016/j.humimm.2004.03.001.Full Text Link to Item
-
Maini, R. N., F. C. Breedveld, J. R. Kalden, J. S. Smolen, D. Furst, M. H. Weisman, E. W. St Clair, et al. “Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.” Arthritis Rheum 50, no. 4 (April 2004): 1051–65. https://doi.org/10.1002/art.20159.Full Text Link to Item
-
Breedveld, F. C., P. Emery, E. Keystone, K. Patel, D. E. Furst, J. R. Kalden, E. W. St Clair, et al. “Infliximab in active early rheumatoid arthritis.” Annals of the Rheumatic Diseases 63, no. 2 (February 2004): 149–55. https://doi.org/10.1136/ard.2003.013961.Full Text
-
Cooper, G. S., E. L. Treadwell, M. A. Dooley, E. W. St Clair, G. S. Gilkeson, and J. A. Taylor. “N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus.” The Journal of Rheumatology 31, no. 1 (January 2004): 76–80.
-
Lamprecht, Peter, and Wolfgang L. Gross. “A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group.” Arthritis Rheum 50, no. 1 (January 2004): 334–35. https://doi.org/10.1002/art.11475.Full Text Link to Item
-
Parks, C. G., G. S. Cooper, M. A. Dooley, E. L. Treadwell, E. W. St Clair, G. S. Gilkeson, and J. P. Pandey. “Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States.” Ann Rheum Dis 63, no. 1 (January 2004): 91–94. https://doi.org/10.1136/ard.2003.007336.Full Text Link to Item
-
Parks, C. G., L. L. Hudson, G. S. Cooper, M. A. Dooley, E. L. Treadwell, E. W. St Clair, G. S. Gilkeson, and J. P. Pandey. “CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States.” Lupus 13, no. 10 (2004): 784–91. https://doi.org/10.1191/0961203304lu1085oa.Full Text Link to Item
-
Geletka, Robin, and E William St Clair. “Treatment of early rheumatoid arthritis.” Best Practice & Research. Clinical Rheumatology 17, no. 5 (October 2003): 791–809. https://doi.org/10.1016/s1521-6942(03)00044-5.Full Text
-
Criscione, Lisa G., Jeremy Sugarman, Linda Sanders, David S. Pisetsky, and E William St Clair. “Informed consent in a clinical trial of a novel treatment for rheumatoid arthritis.” Arthritis Rheum 49, no. 3 (June 15, 2003): 361–67. https://doi.org/10.1002/art.11057.Full Text Link to Item
-
Fraser, Patricia A., Wei-Zi Ding, Mehrdad Mohseni, Edward L. Treadwell, Mary Anne Dooley, E William St Clair, Gary S. Gilkeson, and Glinda S. Cooper. “Glutathione S-transferase M null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: a possible gene-environment interaction for autoimmunity.” J Rheumatol 30, no. 2 (February 2003): 276–82.Link to Item
-
St Clair, E. W. “Infliximab treatment for rheumatic disease: clinical and radiological efficacy.” Ann Rheum Dis 61 Suppl 2, no. Suppl 2 (November 2002): ii67–69. https://doi.org/10.1136/ard.61.suppl_2.ii67.Full Text Link to Item
-
Cooper, Glinda S., Mary Anne Dooley, Edward L. Treadwell, E William St Clair, and Gary S. Gilkeson. “Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history.” J Clin Epidemiol 55, no. 10 (October 2002): 982–89. https://doi.org/10.1016/s0895-4356(02)00429-8.Full Text Link to Item
-
St Clair, E William. “Tides of inflammation: impact of biologics.” The Journal of Rheumatology. Supplement 65 (September 2002): 22–26.
-
Cooper, Glinda S., Mary Anne Dooley, Edward L. Treadwell, E William St Clair, and Gary S. Gilkeson. “Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study.” Arthritis Rheum 46, no. 7 (July 2002): 1830–39. https://doi.org/10.1002/art.10365.Full Text Link to Item
-
Parks, Christine G., Glinda S. Cooper, Leena A. Nylander-French, Wayne T. Sanderson, John M. Dement, Philip L. Cohen, Mary Anne Dooley, et al. “Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States.” Arthritis Rheum 46, no. 7 (July 2002): 1840–50. https://doi.org/10.1002/art.10368.Full Text Link to Item
-
Shanahan, Joseph C., and William St Clair. “Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.” Clin Immunol 103, no. 3 Pt 1 (June 2002): 231–42. https://doi.org/10.1006/clim.2002.5191.Full Text Link to Item
-
St Clair, E William, Carrie L. Wagner, Adedigbo A. Fasanmade, Benjamin Wang, Thomas Schaible, Arthur Kavanaugh, and Edward C. Keystone. “The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.” Arthritis Rheum 46, no. 6 (June 2002): 1451–59. https://doi.org/10.1002/art.10302.Full Text Link to Item
-
Criscione, Lisa G., and E William St Clair. “Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.” Curr Opin Rheumatol 14, no. 3 (May 2002): 204–11. https://doi.org/10.1097/00002281-200205000-00002.Full Text Link to Item
-
Shergy, William J., Reuben A. Isern, David A. Cooley, John L. Harshbarger, J Eugene Huffstutter, Gordon M. Hughes, Elizabeth A. Spencer-Smith, et al. “Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.” The Journal of Rheumatology 29, no. 4 (April 2002): 667–77.
-
Cooper, G. S., C. G. Parks, E. L. Treadwell, E. W. St Clair, G. S. Gilkeson, P. L. Cohen, R. A. S. Roubey, and M. A. Dooley. “Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States.” Lupus 11, no. 3 (2002): 161–67. https://doi.org/10.1191/0961203302lu161oa.Full Text Link to Item
-
Pisetsky, D. S., and E. W. St Clair. “Progress in the treatment of rheumatoid arthritis.” Jama 286, no. 22 (December 12, 2001): 2787–90. https://doi.org/10.1001/jama.286.22.2787.Full Text Link to Item
-
Cooper, G. S., M. A. Dooley, E. L. Treadwell, E. W. St Clair, and G. S. Gilkeson. “Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus.” J Rheumatol 28, no. 12 (December 2001): 2653–56.Link to Item
-
St Clair, E. W. “Radiographic joint damage in rheumatoid arthritis: a community-based perspective.” Arthritis Rheum 44, no. 6 (June 2001): 1231–33. https://doi.org/10.1002/1529-0131(200106)44:6<1231::AID-ART212>3.0.CO;2-2.Full Text Link to Item
-
St Clair, E. W., W. E. Wilkinson, D. S. Pisetsky, D. J. Sexton, R. Drew, V. B. Kraus, and R. A. Greenwald. “The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.” Arthritis Rheum 44, no. 5 (May 2001): 1043–47. https://doi.org/10.1002/1529-0131(200105)44:5<1043::AID-ANR183>3.0.CO;2-C.Full Text Link to Item
-
Stone, J. H., G. S. Hoffman, P. A. Merkel, Y. I. Min, M. L. Uhlfelder, D. B. Hellmann, U. Specks, et al. “A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).” Arthritis Rheum 44, no. 4 (April 2001): 912–20. https://doi.org/10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5.Full Text Link to Item
-
Pandey, J. P., G. S. Cooper, E. L. Treadwell, G. S. Gilkeson, E. W. St Clair, and M. A. Dooley. “Immunoglobulin GM and KM allotypes in systemic lupus erythematosus.” Exp Clin Immunogenet 18, no. 3 (2001): 117–22. https://doi.org/10.1159/000049190.Full Text Link to Item
-
Lipsky, P. E., D. M. van der Heijde, E. W. St Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, et al. “Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.” N Engl J Med 343, no. 22 (November 30, 2000): 1594–1602. https://doi.org/10.1056/NEJM200011303432202.Full Text Link to Item
-
St Clair, E. W., S. B. Cohen, M. L. Lee, R. M. Fleischmann, S. H. Lee, L. W. Moreland, N. J. Olsen, et al. “Treatment of rheumatoid arthritis with a DR4/1 peptide.” J Rheumatol 27, no. 8 (August 2000): 1855–63.Link to Item
-
Hamilton, K., and E. W. Clair. “Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.” Expert Opin Pharmacother 1, no. 5 (July 2000): 1041–52. https://doi.org/10.1517/14656566.1.5.1041.Full Text Link to Item
-
Levesque, M. C., D. A. Mackin, J. A. Fleming, and E. W. St Clair. “Serum levels of soluble CD44 in primary Sjögren's syndrome.” J Rheumatol 27, no. 6 (June 2000): 1444–49.Link to Item
-
Kavanaugh, A., E. W. St Clair, W. J. McCune, T. Braakman, and P. Lipsky. “Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.” The Journal of Rheumatology 27, no. 4 (April 2000): 841–50.
-
St Clair, E. W. “Interleukin-10: therapeutic prospects in rheumatoid arthritis.” Curr Dir Autoimmun 2 (2000): 126–49. https://doi.org/10.1159/000060501.Full Text Link to Item
-
St Clair, E. W. “Interleukin 10 treatment for rheumatoid arthritis.” Annals of the Rheumatic Diseases 58, no. SUPPL. 1 (December 16, 1999).
-
Maini, R., E. W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, et al. “Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.” Lancet 354, no. 9194 (December 4, 1999): 1932–39. https://doi.org/10.1016/s0140-6736(99)05246-0.Full Text Link to Item
-
St Clair EW, C. L. “Therapy of rheumatoid arthritis: new developments and trends.” Curr Rheumatol Rep 1, no. 2 (December 1999): 149–56. https://doi.org/10.1007/s11926-999-0012-6.Full Text Link to Item
-
Verma, A., E. W. St Clair, and R. A. Radtke. “A case of sustained massive gabapentin overdose without serious side effects.” Ther Drug Monit 21, no. 6 (December 1999): 615–17. https://doi.org/10.1097/00007691-199912000-00006.Full Text Link to Item
-
St Clair, E. W. “Interleukin 10 treatment for rheumatoid arthritis.” Ann Rheum Dis 58 Suppl 1, no. Suppl 1 (November 1999): I99–102. https://doi.org/10.1136/ard.58.2008.i99.Full Text Link to Item
-
Williams, H. J., G. S. Alarcon, R. Joks, V. D. Steen, K. Bulpitt, D. O. Clegg, C. M. Ziminski, et al. “Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD.” J Rheumatol 26, no. 4 (April 1999): 816–25.Link to Item
-
Moreland, L. W., and E. W. St Clair. “The use of analgesics in the management of pain in rheumatic diseases.” Rheumatic Diseases Clinics of North America 25, no. 1 (February 1999): 153–vii. https://doi.org/10.1016/s0889-857x(05)70059-4.Full Text
-
St Clair, E. W., and R. M. McCallum. “Cogan's syndrome.” Curr Opin Rheumatol 11, no. 1 (January 1999): 47–52. https://doi.org/10.1097/00002281-199901000-00008.Full Text Link to Item
-
Hansen, K. E., and E. W. St Clair. “Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature.” Semin Arthritis Rheum 28, no. 3 (December 1998): 193–99. https://doi.org/10.1016/s0049-0172(98)80036-x.Full Text Link to Item
-
Perkins, D. J., E. W. St Clair, M. A. Misukonis, and J. B. Weinberg. “Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2).” Arthritis Rheum 41, no. 12 (December 1998): 2205–10. https://doi.org/10.1002/1529-0131(199812)41:12<2205::AID-ART16>3.0.CO;2-Q.Full Text Link to Item
-
Cooper, G. S., M. A. Dooley, E. L. Treadwell, E. W. St Clair, C. G. Parks, and G. S. Gilkeson. “Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus.” Arthritis and Rheumatism 41, no. 10 (October 1998): 1714–24. https://doi.org/10.1002/1529-0131(199810)41:103.0.CO;2-U.Full Text
-
Cooper, G. S., M. A. Dooley, E. L. Treadwell, E. W. St Clair, C. G. Parks, and G. S. Gilkeson. “Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus.” Arthritis Rheum 41, no. 10 (October 1998): 1714–24. https://doi.org/10.1002/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U.Full Text Link to Item
-
St Clair, E. W. “Nitric oxide--friend or foe in arthritis?” J Rheumatol 25, no. 8 (August 1998): 1451–53.Link to Item
-
St Clair, E. W., S. A. Moak, W. E. Wilkinson, L. Sanders, T. Lang, and R. A. Greenwald. “A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.” J Rheumatol 25, no. 8 (August 1998): 1472–79.Link to Item
-
Barnett, M. L., J. M. Kremer, E. W. St Clair, D. O. Clegg, D. Furst, M. Weisman, M. J. Fletcher, et al. “Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.” Arthritis Rheum 41, no. 2 (February 1998): 290–97. https://doi.org/10.1002/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R.Full Text Link to Item
-
Kremer, J. M., G. S. Alarcón, M. E. Weinblatt, M. V. Kaymakcian, M. Macaluso, G. W. Cannon, W. R. Palmer, et al. “Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.” Arthritis Rheum 40, no. 10 (October 1997): 1829–37. https://doi.org/10.1002/art.1780401016.Full Text Link to Item
-
Alarcón, G. S., J. M. Kremer, M. Macaluso, M. E. Weinblatt, G. W. Cannon, W. R. Palmer, E. W. St Clair, et al. “Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.” Ann Intern Med 127, no. 5 (September 1, 1997): 356–64. https://doi.org/10.7326/0003-4819-127-5-199709010-00003.Full Text Link to Item
-
Pisetsky, D. S., G. Gilkeson, and E. W. St Clair. “Systemic lupus erythematosus. Diagnosis and treatment.” Med Clin North Am 81, no. 1 (January 1997): 113–28. https://doi.org/10.1016/s0025-7125(05)70507-1.Full Text Link to Item
-
St Clair, E. W., W. E. Wilkinson, T. Lang, L. Sanders, M. A. Misukonis, G. S. Gilkeson, D. S. Pisetsky, D. I. Granger, and J. B. Weinberg. “Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients.” J Exp Med 184, no. 3 (September 1, 1996): 1173–78. https://doi.org/10.1084/jem.184.3.1173.Full Text Link to Item
-
Conlon, P. J., C. A. Fischer, M. C. Levesque, S. R. Smith, E. W. St Clair, N. B. Allen, J. A. Fleming, and D. N. Howell. “Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.” Clin Nephrol 46, no. 3 (September 1996): 170–75.Link to Item
-
Olsen, N. J., R. H. Brooks, J. J. Cush, P. E. Lipsky, E. W. St Clair, E. L. Matteson, K. N. Gold, et al. “A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.” Arthritis Rheum 39, no. 7 (July 1996): 1102–8. https://doi.org/10.1002/art.1780390705.Full Text Link to Item
-
St Clair, E. W., and J. A. Burch. “In vitro RNA selection of an autoimmune epitope on stem-loop II of U1 RNA.” Clin Immunol Immunopathol 79, no. 1 (April 1996): 60–70. https://doi.org/10.1006/clin.1996.0051.Full Text Link to Item
-
Isaacs, J. D., V. K. Manna, N. Rapson, K. J. Bulpitt, B. L. Hazleman, E. L. Matteson, E. W. St Clair, T. J. Schnitzer, and J. M. Johnston. “CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.” British Journal of Rheumatology 35, no. 3 (March 1996): 231–40. https://doi.org/10.1093/rheumatology/35.3.231.Full Text
-
Goel, N., D. T. Ulrich, E. W. St Clair, J. A. Fleming, D. H. Lynch, and M. F. Seldin. “Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.” Arthritis Rheum 38, no. 12 (December 1995): 1738–43. https://doi.org/10.1002/art.1780381206.Full Text Link to Item
-
Waugh, R. A., E. W. St Clair, and E. Z. Oddone. “Bedside science reduces laboratory art.” Circulation 92, no. 9 (November 1, 1995): 2762.Link to Item
-
Matteson, E. L., D. E. Yocum, E. W. St Clair, A. A. Achkar, M. S. Thakor, M. R. Jacobs, A. E. Hays, C. K. Heitman, and J. M. Johnston. “Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection.” Arthritis Rheum 38, no. 9 (September 1995): 1187–93. https://doi.org/10.1002/art.1780380903.Full Text Link to Item
-
St Clair, E. W., J. A. Burch, and M. Saitta. “Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens.” Arthritis Rheum 37, no. 9 (September 1994): 1373–79. https://doi.org/10.1002/art.1780370916.Full Text Link to Item
-
Bloom, D. D., E. W. St Clair, D. S. Pisetsky, and S. H. Clarke. “The anti-La response of a single MRL/Mp-lpr/lpr mouse: specificity for DNA and VH gene usage.” Eur J Immunol 24, no. 6 (June 1994): 1332–38. https://doi.org/10.1002/eji.1830240614.Full Text Link to Item
-
Kingsmore, S. F., O. E. Silva, B. D. Hall, E. A. Sheldon, L. D. Cripe, and E. W. St Clair. “Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash.” J Rheumatol 20, no. 9 (September 1993): 1588–91.Link to Item
-
St Clair, E. W. “New developments in Sjögren's syndrome.” Current Opinion in Rheumatology 5, no. 5 (September 1993): 604–12. https://doi.org/10.1097/00002281-199305050-00008.Full Text
-
St Clair, E. W., and B. F. Haynes. “The future of rheumatoid arthritis treatment.” Bull Rheum Dis 42, no. 2 (April 1993): 1–4.Link to Item
-
St Clair, E. W., E. Z. Oddone, R. A. Waugh, G. R. Corey, and J. R. Feussner. “Assessing housestaff diagnostic skills using a cardiology patient simulator.” Ann Intern Med 117, no. 9 (November 1, 1992): 751–56. https://doi.org/10.7326/0003-4819-117-9-751.Full Text Link to Item
-
St Clair, E. W. “Anti-La antibodies.” Rheumatic Diseases Clinics of North America 18, no. 2 (May 1992): 359–76.
-
St Clair, E. W. “Sjögren's syndrome and autoimmunity.” Concepts in Immunopathology 8 (January 1992): 161–88.
-
St Clair, E. W., J. C. Angellilo, and K. H. Singer. “Expression of cell-adhesion molecules in the salivary gland microenvironment of Sjögren's syndrome.” Arthritis Rheum 35, no. 1 (January 1992): 62–66. https://doi.org/10.1002/art.1780350110.Full Text Link to Item
-
St Clair, E. W., D. Kenan, J. A. Burch, J. D. Keene, and D. S. Pisetsky. “Anti-La antibody production by MRL-1pr/1pr mice. Analysis of fine specificity.” J Immunol 146, no. 6 (March 15, 1991): 1885–92.Link to Item
-
St Clair, E. W., D. Kenan, J. A. Burch, J. D. Keene, and D. S. Pisetsky. “The fine specificity of anti-La antibodies induced in mice by immunization with recombinant human La autoantigen.” J Immunol 144, no. 10 (May 15, 1990): 3868–76.Link to Item
-
St Clair, E. W., C. C. Query, R. Bentley, J. D. Keene, R. P. Polisson, N. B. Allen, D. S. Caldwell, J. R. Rice, C. Cox, and D. S. Pisetsky. “Expression of autoantibodies to recombinant (U1) RNP-associated 70K antigen in systemic lupus erythematosus.” Clin Immunol Immunopathol 54, no. 2 (February 1990): 266–80. https://doi.org/10.1016/0090-1229(90)90088-8.Full Text Link to Item
-
St Clair, E. W., J. A. Burch, M. M. Ward, J. D. Keene, and D. S. Pisetsky. “Temporal correlation of antibody responses to different epitopes of the human La autoantigen.” J Clin Invest 85, no. 2 (February 1990): 515–21. https://doi.org/10.1172/JCI114467.Full Text Link to Item
-
St Clair, E. W., N. Talal, H. M. Moutsopoulos, A. Ballester, L. Zerva, J. D. Keene, and D. S. Pisetsky. “Epitope specificity of anti-La antibodies from patients with Sjögren's syndrome.” J Autoimmun 2, no. 4 (August 1989): 335–44. https://doi.org/10.1016/0896-8411(89)90161-3.Full Text Link to Item
-
Manzi, S., V. B. Kraus, and E. W. St Clair. “An unusual photoactivated skin eruption. Quinidine-induced livedo reticularis.” Arch Dermatol 125, no. 3 (March 1989): 417–22. https://doi.org/10.1001/archderm.1989.01670150109020.Full Text Link to Item
-
St Clair, E. W., D. S. Pisetsky, C. F. Reich, and J. D. Keene. “Analysis of autoantibody binding to different regions of the human La antigen expressed in recombinant fusion proteins.” J Immunol 141, no. 12 (December 15, 1988): 4173–80.Link to Item
-
St Clair, E. W., D. S. Pisetsky, C. F. Reich, J. C. Chambers, and J. D. Keene. “Quantitative immunoassay of anti-La antibodies using purified recombinant La antigen.” Arthritis Rheum 31, no. 4 (April 1988): 506–14. https://doi.org/10.1002/art.1780310407.Full Text Link to Item
-
Simel, D. L., E. W. St Clair, J. Adams, and C. S. Greenberg. “Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome.” Am J Med 83, no. 3 (September 1987): 563–66. https://doi.org/10.1016/0002-9343(87)90772-8.Full Text Link to Item
-
St Clair, E. W., and R. P. Polisson. “Therapeutic approaches to the treatment of rheumatoid disease.” Med Clin North Am 70, no. 2 (March 1986): 285–304. https://doi.org/10.1016/s0025-7125(16)30954-3.Full Text Link to Item
-
St Clair, E. W., J. R. Rice, and R. Snyderman. “Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis.” Arch Intern Med 145, no. 11 (November 1985): 2035–38. https://doi.org/10.1001/archinte.145.11.2035.Full Text Link to Item
-
St Clair, W., B. Jones, J. S. Rogers, M. Crouch, and E. Hrabovsky. “Deep venous thrombosis and a circulating anticoagulant in systemic lupus erythematosus.” Am J Dis Child 135, no. 3 (March 1981): 230–32. https://doi.org/10.1001/archpedi.1981.02130270022008.Full Text Link to Item
-
-
Book Sections
-
McCallum, R. M., E. W. St.Clair, and B. F. Haynes. “Cogan's syndrome.” In Inflammatory Diseases of Blood Vessels, 491–509, 2016.
-
Dye, J. R., M. S. Kaul, and E. W. St. Clair. “Inflammatory Diseases of the Coronary Arteries.” In PanVascular Medicine, Second Edition, 1885–1916, 2015. https://doi.org/10.1007/978-3-642-37078-6_64.Full Text
-
-
Conference Papers
-
Berti, Alvise, Roscoe Warner, Kent Johnson, Divi Cornec, Darrell Schroeder, Brian Kabat, Carol A. Langford, et al. “Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.” In Arthritis Rheumatol, 70:1114–21, 2018. https://doi.org/10.1002/art.40471.Full Text Link to Item
-
St Clair, E. W. “Infliximab treatment for rheumatic disease: Clinical and radiological efficacy.” In Annals of the Rheumatic Diseases, Vol. 61, 2002.
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.